# A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

> **NCT05668988** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Dizal Pharmaceuticals** · enrollment: 324 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** sunvozertinib
- **DRUG:** Pemetrexed+carboplatin

## Key facts

- **NCT ID:** NCT05668988
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2026-01-16
- **Final completion:** 2027-10-31
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668988, "A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05668988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*